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Abstract
Glycogen synthase kinase-3 (GSK-3) inhibitors have been postulated as useful therapeutic tools for the treatment of chronic
neurodegenerative and neuropsychiatric diseases. Nevertheless the clinical use of these inhibitors has been limited by their
common side effects. Lithium, a non-selective GSK-3 inhibitor has been classically administered to treat bipolar patients but
its prescription is decreasing due to its frequent side effects such as hand tremor. This toxicity seems to be higher in the
elderly and a clinical trial with lithium for Alzheimer’s disease was stopped due to high rate of discontinuation. We have
previously described a mechanism for the adverse effects of chronic lithium that involves neuronal apoptosis via Fas
signaling. As lithium inhibits many other enzymatic activities such as inositol monophosphatase and histone deacetylase,
here we aim to genetically test whether GSK-3 inhibition induces those adverse effects through Fas receptor. For this
purpose we took advantage of a transgenic mouse line with decreased GSK-3 activity (Tet/DN-GSK-3 mice) that shows
increased rate of neuronal apoptosis as well as motor deficits and brought it to a Fas deficient background (lpr mice). We
found that apoptosis induced by GSK-3 inhibition was absent in Fas deficient background. Interestingly, motor deficits were
also absent in Fas deficient Tet/DN-GSK-3 mice. These results demonstrate that Fas signaling contributes to the neurological
toxicity of GSK-3 inhibition and suggest that a combination of GSK-3 inhibitors with blockers of Fas signaling could help to
improve the application of GSK-3 inhibitors to clinics.
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Introduction
GKS-3 is involved in many cellular signaling pathways such as
the insulin/PI3K or the Wnt pathways and participates in a high
number of functions such as metabolism, cell proliferation, cell
fate, survival and apoptosis [1,2,3,4,5]. Besides, it also plays a key
role in certain neuronal specific functions like long term
potentiation (LTP) and depression (LTD) of synaptic activity
[6,7]. Dysregulation of GSK-3 has been postulated to participate
in the etiology of neuropsychiatric or neurodegenerative diseases:
bipolar disorder [8,9,10], schizophrenia [9,11], Alzheimer’s
disease (AD) [3,12,13] or Huntington’s disease [14,15,16] and of
non-CNS diseases: type 2 diabetes [17] or cancer [18]. Conse-
quently, GSK-3 inhibitors have been postulated as a promising
therapeutic tool [19,20]. Lithium inhibits GSK-3 [21,22,23] and
this has been postulated to contribute to its therapeutic efficacy
[8,9,10] but also to its neurological toxicity [24]. Together, this
lithium’s adverse effects [25] and those of GSK-3 genetic
inhibition [26,27] warn about possible limitations of GSK-3
inhibitor based therapies. Understanding of the mechanism of this
toxicity and of how to counteract it may be a key step for successful
therapeutic use of GSK-3 inhibitors.
GSK-3 is implicated in apoptosis but its modulatory effect can
be different depending on the specific apoptotic pathway involved:
intrinsic (type I) that involves release of cytochrome c and
disintegration of mitochondria and extrinsic (type II) apoptosis that
occurs upon the activation of death receptors, specifically the TNF
receptor family including Fas and TRAIL [28]. Consequently,
lithium and other GSK-3 inhibitors are protective towards many
apoptotic stimuli that affect mitochondrial integrity but increase
apoptosis triggered by TNF [26,29] or Fas [30]. Conceivably, this
may have significant implications on the therapeutic potential of
GSK-3 inhibitors.
Mice with conditional expression of a dominant negative form
of GSK-3 (Tet/DN-GSK-3 mice) [27] are a useful tool to explore
the neurological consequences of chronically decreasing GSK-3
activity in the brain [24]. Tet/DN-GSK-3 mice display increased
rate of neuronal apoptosis and impaired motor coordination [27]
that might relate to the frequent neurological motor side effects,
such as hand tremor, experienced by lithium-treated patients [25].
Interestingly, wild type mice chronically treated with lithium also
show increased rate of neuronal apoptosis and a deficit in motor
coordination that have been reported to occur through a
mechanism involving Fas, as they are absent in Fas-deficient mice
(lpr mice) [24]. Since lithium inhibits other enzymes like inositol-
monophosphatase or histone-deacetylase [31], it cannot be
ascertained that this toxicity mechanism is due to GSK-3
inhibition. Here we test if apoptosis and related behavioral
consequences due to decreased GSK-3 activity are Fas dependent.
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Figure 1. Generation of experimental mice and analysis of body weight. A. Diagram showing the breeding design. First, lpr/+;Tet/DN-GSK-3
and lpr/+ mice (F1) were obtained by crossing lpr/lpr mice with Tet/DN-GSK-3 or wt mice respectively (F0). Then, lpr/+;Tet/DN-GSK-3 and lpr/+ mice
were combined to obtain 12 possible genotypes among which we obtained the 6 experimental groups: wt, Tet/DN-GSK-3, lpr/+, lpr/+;Tet/DN-GSK-3,
lpr/lpr and lpr/lpr;Tet/DN-GSK-3. B. Identification of the different genotypes by PCR to detect the CamKII-tTA and the DN-GSK-3 transgenes and the
presence of the lpr mutation. Line 1: wt; line 2: Tet/DN-GSK-3; line 3: lpr/+; line 4: lpr/+; Tet/DN-GSK-3; line 5: lpr/lpr; line 6: lpr/lpr; Tet/DN-GSK-3.
Analysis of the transgene expression by western blot in striatum the six experimental genotypes and example of immunohistochemistry of the
reporter b-gal in striatum (St) of Tet/DN-GSK-3 mice. Scale bar corresponds to 100 mm. ac, anterior commissure; GP, globus pallidus. C. Body weight of
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Materials and Methods
Animals
Tet/DN-GSK-3 mice in a C57/BL6J background were
generated as described previously [27]. Fas-deficient lpr mice
(C57/BL/6J background) were obtained from Jackson laborato-
ries (B6.MRL-Faslpr/J, stock number: 000482). All mice were
housed at the Centro de Biologı´a Molecular ‘‘Severo Ochoa’’
animal facility. Mice were housed four per cage with food and
water available ad libitum and maintained in a temperature-
controlled environment on a 12/12 h light-dark cycle with light
onset at 07:00 h. For behavioral analysis, mice were tested at the
age of 2.5–3 months and they were sacrificed upon completion of
the battery of tests. For histological studies only male mice were
used. For behavioral studies males and females were used
indistinctly. Statistical analysis as genotype x treatment interaction
was evaluated by two way-ANOVA to rule out any effect of sex.
All behavioral studies were performed during light phase.
Ethics Statement
Animal housing and maintenance protocols followed the
guidelines of Council of Europe Convention ETS123, recently
revised as indicated in the Directive 86/609/EEC. Animal
experiments were performed under protocols (P15/P16/P18/
P22) approved by the Centro de Biologı´a Molecular Severo Ochoa
Institutional Animal Care and Utilization Committee (Comite´ de
E´tica de Exerimentacio´n Animal del CBM, CEEA-CBM),
Madrid, Spain.
PCR
Mice were genotyped by using the following primers:
For detection of the CamKII-tTA (tTA) transgene: primer tTA-
C (59-ACTAAGTCATCGGATGGAGC-39) and primer tTA-F
(59-CGAAATCGTCTAGCGCGTCGG-39) that amplify a
592 bp fragment. For detection of the DN-GSK-3 (tetO-R4)
transgene: primer GSK-3A (59- CATGGTCAGGTCATGGAT-
GAGC-39) and primer GSK-3B (59-TAATCAGCCACTGATC-
CACCCAG-39) that amplify a 642 bp fragment. Amplification
protocol used for both combinations was: 5 min at 94uC followed
by 30 cycles of 53uC for 1 min, 72uC for 1,5 min, and 94uC for
1 min and finally 72uC for 5 min. For discriminating the lpr
mutation we used the protocol recommended by Jackson
Laboratories with the three following primers: wild type (59-
CAAATCTAGGCATTAACAGTG-39), mutant (59-TAGAAAG
GTGCACGGGTGTG) and common (59-GTAAATAATTGT
GCTTCGTCAG-39) that yield a 179 bp band from the wild type
allele and a 217 bp band from the mutant allele.
Western Blot Analysis
Mice were sacrificed using CO2 and brains immediately
removed and dissected on an ice-cold plate. Whole extracts were
prepared by homogenizing the brain areas from right hemisphere
in ice-cold extraction buffer consisting of 20 mM HEPES pH 7.4,
100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 mM sodium
orthovanadate, 1 mM okadaic acid, 5 mM sodium pyrophosphate,
30 mM b-glycerophosphate, 5 mM EDTA, and protease inhibi-
tors (2 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin and
10 mg/ml pepstatin). Samples were homogenized and centrifuged
at 15000 g for 20 min at 4uC. The resulting supernatant was
collected, and protein content determined by Bradford assay.
Fifteen micrograms of total protein were electrophoresed on 10%
SDS-polyacrylamide gel and transferred to a nitrocellulose
membrane (Schleicher and Schuell). The experiments were
performed using the following primary antibodies: anti-b-gal
(Promega, 1:2000) and anti-b-actin (Sigma, 1:5000). The mem-
branes were incubated with antibody overnight at 4uC in 5% non-
fat dried milk. Secondary antibodies used were polyclonal rabbit
anti-mouse immunoglobulins/HRP (DAKO Cytomation) (1:2000)
and ECL detection reagents (Perkin Elmer) were used for
immunodetection.
Immunofluorescence and Immunohistochemistry
Left hemispheres were processed for histology placed in 4%
paraformaldehyde in Sorensen’s phosphate buffer (PFA) over-
night, washed in PBS and then immersed in 30% sucrose in PBS
for 72 hr. Once cryoprotected, the samples were included in OCT
compound (Sakura Finetek Europe) frozen and stored at 280uC
until use. 30 mm sagittal sections were cut on a CM 1950 Ag
Protect freezing microtome (Leica) and collected and stored free
all resulting genotypes was measured at the age of 2.5 months. One-way ANOVA test followed by Bonferroni post-hoc test was applied to determine
the level of significance. The number of analyzed animals is indicated in the graph. Only lpr/lpr mice were significantly different than wt mice (*
p,0.05).
doi:10.1371/journal.pone.0070952.g001
Table 1. Genotype frequencies.
Nomenclature wt tTA tetO-R4 Tet/DN-GSK-3 lpr/+ lpr/+;tTA lpr/+;tetO-R4 lpr/+;Tet/DN-
GSK-3
lpr/lpr lpr/lpr;tTA lpr/lpr;tetO-R4 lpr/lpr;Tet/
DN-GSK-3
lpr locus +/+ +/+ +/+ +/+ lpr/+ lpr/+ lpr/+ lpr/+ lpr/lpr lpr/lpr lpr/lpr lpr/lpr
Tet/DN-GSK-3
transgenes
– tTA tetO-R4 tTA+tetO-R4 – tTA tetO-R4 tTA+tetO-R4 – tTA tetO-R4 tTA+tetO-R4
Distribution/frequencies
N 28 32 20 21 67 37 34 37 27 21 13 10
Expected
frequencies
6.25 6.25 6.25 6.25 12.5 12.5 12.5 12.5 6.25 6.25 6.25 6.25
Observed
frequencies
8.07 9.22 5.76 6.05 19.31 10.66 9.8 10.66 7.78 6.05 3.75 2.88
doi:10.1371/journal.pone.0070952.t001
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floating in glycol containing buffer (30% glycerol, 30% ethylene
glycol in 0,02 M phosphate buffer) at 220uC.
For immunofluorescence, 30 mm sagittal brain sections were
pretreated with 0,1% Triton X-100 for 15 min, 1 M Glycine for
30 min, and blocking solution (1% BSA and 0,1% Triton X-100)
for 1 hour. Sections were then incubated overnight at 4uC with
primary antibodies in blocking solution at the following concen-
trations: cleaved-caspase-3 (Cell Signaling Technology, MA)
(1:50), b-gal (Promega) 1:2000 and NeuN (Chemicon) (1:100).
The following day, sections were washed in PBS. Then sections
were incubated with donkey anti-rabbit Alexa 555 (Invitrogen)
(1:500), donkey anti-mouse Alexa 488 (Invitrogen) (1:1000) and
goat anti-mouse Alexa 488 (Invitrogen) (1:1000) secondary
antibodies for 1 hour. Finally, nuclei were counterstained with
DAPI (1:5000, Calbiochem). Sections were mounted on glass
slides, coverslipped with Fluorsave (Calbiochem) and maintained
at 4uC.
Colocalization of markers was identified by taking successive
Alexa 555 and Alexa 488 fluorescent images using a Laser
Confocal LSM710 camera (Zeiss) coupled to an inverted
microscope AxioObserver (Zeiss).
For immunohistochemistry, brain sections were pretreated for
30 min in 1%H2O2/PBS followed by 1 h with 1% BSA, 5% FBS
and 0.2% Triton X-100 and incubated overnight at 4uC with b-
gal (ICN Biomed.-Cappel, 1:2000) or cleaved-caspase-3 (Cell
Signaling, 1:50) primary antibodies. Finally, brain sections were
incubated in avidin-biotin complex using the Elite Vectastain kit
(Vector Laboratories). Chromogen reactions were performed with
diaminobenzidine (SIGMAFASTTM DAB, Sigma) for 10 min.
Sections were mounted on glass slides and coverslipped with
Fluorosave (Calbiochem). For quantification of cleaved-caspase-3
immunostainings, four male mice per genotype were processed as
follows: one every four serial 30 mm-sagittal sections were selected
for staining between the 3.00 mm and 0.72 mm planes of the
Paxinos and Franklin mouse brain atlas [32]. Round-shape (5–
10 mm in diameter) positive cells were quantified with the
‘‘Analyze particles’’ tool of Image J. Non-round shape cells with
characteristic apoptotic bodies were detected manually. All
analyses were performed blind and results were presented as the
estimate of total positive cells in the whole brain structure.
TUNEL Assay
Sections were processed according to the In Situ Cell Death
Detection Kit protocol (POD, Roche). Quantification was
performed on 4 male mice per genotype by staining one every
four serial 30 mm-sagittal sections spanning from the 3.00 mm to
the 0.72 mm planes of the Paxinos and Franklin mouse brain atlas
[32]. Round-shape (5–10 mm in diameter) positive cells were
quantified with the ‘‘Analyze particles’’ tool of Image J. All
analyses were performed blind and results were presented as the
Figure 2. Analysis of apoptotic levels in experimental mice. A.
Double labeling immunofluoresce with anti-cleaved caspase-3 (red) and
b-gal (green) antibodies. Scale bar in left panel corresponds to 20 mm. B.
Double labeling immunofluoresce with anti-cleaved caspase-3 (red) and
NeuN (green) antibodies. Right panel shows a merged image of
caspase-3, NeuN and dapi counterstaining. Scale bar in left panel
corresponds to 10 mm. C. Immunohistochemistry with anti-cleaved
caspase-3 antibody. Left panels correspond to Cx (upper) and St (lower)
of Tet/DN-GSK-3. Right panels correspond to Cx (upper) and St (lower)
of lpr/lpr;Tet/DN-GSK-3. Scale bar in upper left panel corresponds to
50 mm. D. Quantification of caspase-3 positive cells in cortex (Cx),
striatum (St), thalamus (Thal) and cerebellum (Cb) of wt, Tet/DN-GSK-3,
lpr/+, lpr/+;Tet/DN-GSK-3, lpr/lpr and lpr/lpr;Tet/DN-GSK-3 mice (4 male
mice per genotype). For quantification, one every four serial 30 mm-
sagittal sections were selected for staining between the 3.00 mm and
0.72 mm planes of the Paxinos and Franklin mouse brain atlas [32].
Then, the total number of positive cells was extrapolated for the whole
structure. E. TUNEL staining. Low magnification pictures were captured
at 206, insets were taken at 406. Representative images correspond to
St of Tet/DN-GSK-3 (left panel) and lpr/lpr;Tet/DN-GSK-3 (right panel).
Scale bar corresponds to 50 mm. F. Quantification of TUNEL positive
cells in cortex (Cx), striatum (St), thalamus (Thal) and cerebellum (Cb) of
wt, Tet/DN-GSK-3, lpr/+, lpr/+;Tet/DN-GSK-3, lpr/lpr and lpr/lpr;Tet/DN-
GSK-3 mice. Quantification was performed as for Caspase-3 quantifica-
tion. The number of animals included in this analysis is 4 male animals
per genotype. Data are presented as the mean 6 s.e.m. number of
positive cells per 30 mm section for each structure. Statistical analysis of
cleaved caspase-3 immunohistochemistry and TUNEL was performed
following a one way-ANOVA test followed by a LSD post-hoc test. *,#
p,0.05; **,## p,0.01; ***,### p,0.001. * for wt vs. Tet/DN-GSK-3;
# for Tet/DN-GSK-3 vs. lpr/+;Tet/DN-GSK-3 and lpr/lpr;Tet/DN-GSK-3
mice.
doi:10.1371/journal.pone.0070952.g002
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Figure 3. Motor deficits in Tet/DN-GSK-3 mice are Fas dependent. A–D. Analysis of gait parameters by using the DigiGait apparatus. Analysis
of swing duration (A), stride length variability (B), paw angle variability (C) and paw area variability (D) of experimental mice (wt, n = 13; Tet/DN-GSK-3,
n = 12; lpr/+, n = 21; lpr/+;Tet/DN-GSK-3, n = 21; lpr/lpr, n = 14 and lpr/lpr;Tet/DN-GSK-3, n = 8). Statistical analysis of swing duration, stride length
GSK-3 Inhibition Toxicity is Fas-Dependent
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estimate of total TUNEL-positive cells in the whole brain
structure.
Behavioral Testing
Treadmill gait analysis. Gait analysis was performed using
the DigiGaitTM system (Mouse Specifics Inc., Boston, MA) [33].
Briefly, digital images of paw placement were recorded at 80 Hz
through a clear treadmill from beneath the animal. Mice were
tested without pre-training in one session at a treadmill speed of
24 cm/s. Paws were marked with red colorant for better contrast.
Plotting the area of each digital paw print imaged sequentially in
time provides a dynamic gait signal, representing the temporal
record of paw placement relative to the treadmill belt. Swing
duration was measured as the time duration of the swing phase,
when no paw is in contact with the belt. Paw angle variability is
the variability of paw angle, considered as the angle that the paw
makes with the long axis of the direction of motion. Stride length
variation represents the standard deviation of the stride length for
the set of strides recorded (reflecting the dispersion about the
average value) [33]. Step angle variation was measured as CV and
was calculated using the equation: 100 x standard deviation/mean value
(variability normalized to the mean). Step angle factors both stance
width and stride length. Stance asymmetry is the ratio of left hind
limb stance to right hind limb. The number of animals used for
this test was: wt, n = 14 (5 males/9 females); Tet/DN-GSK-3,
n = 12 (4 males/8 females); lpr/+, n = 22 (13 males/9 females);
lpr/+;Tet/DN-GSK-3, n = 23 (12 males/11 females); lpr/lpr,
n = 15 (11 males/4 females) and lpr/lpr;Tet/DN-GSK-3, n = 9 (5
males/4 females).
Vertical pole test. Testing was performed as previously
described [34] with minor modifications [27]. The mouse was
placed head-upward on the top of a vertical rough-surfaced pole
(diameter 1 cm; height 50 cm) and the time taken to descend to
the floor was recorded with a maximum duration of 60 s. The
number of animals used for this test was: wt, n = 16 (6 males/10
females); Tet/DN-GSK-3, n = 18 (10 males/8 females); lpr/+,
n = 28 (16 males/12 females); lpr/+;Tet/DN-GSK-3, n = 23 (12
males/11 females); lpr/lpr, n = 16 (13 males/3 females) and lpr/
lpr;Tet/DN-GSK-3, n = 10 (5 males/5 females).
Rotarod. Test was performed with accelerating rotarod
apparatus (Ugo Basile, Comerio, Italy). Mice were pre-trained
during two days at a constant speed, 4 rpm the first day or 8 rpm
the second day. Then, rotarod was set to accelerate from 4 to
40 rpm over 5 min and mice were tested four times. During
accelerating trials, the latency to fall from the rod was measured.
The number of animals used for this test was: wt, n = 16 (6 males/
10 females); Tet/DN-GSK-3,n = 19 (10 males/9 females); lpr/+,
n = 28 (15 males/13 females); lpr/+;Tet/DN-GSK-3, n = 25 (13
males/12 females); lpr/lpr, n = 16 (12 males/4 females) and lpr/
lpr;Tet/DN-GSK-3, n = 10 (5 males/5 females).
Open Field. Locomotor activity was measured in clear
plexiglas boxes measuring 43.2 cm643.2 cm, outfitted with
photo-beam detectors for monitoring horizontal and vertical
activity. Activity levels were recorded with a MED Associates’
Activity Monitor (MED Associates, St. Albans, VT). Locomotor
activity data were collected via a PC and was analyzed with the
MED Associates’ Activity Monitor Data Analysis software. Mice
were placed in a corner of the open-field apparatus and left to
move freely. Variables recorded included: resting time (s),
ambulatory time (s), vertical/rearing time (s), jump time (s),
stereotypic time (s) and average velocity (cm/s). Data were
individually recorded for each animal during 15 min.
The number of animals used for this test was: wt, n = 6 (2
males/4 females); Tet/DN-GSK-3,n = 6 (1 male/5 females); lpr/
+, n = 11 (7 males/4 females); lpr/+;Tet/DN-GSK-3, n = 14 (8
males/6 females); lpr/lpr, n = 12 (5 males/7 females) and lpr/
lpr;Tet/DN-GSK-3, n = 6 (3 males/3 females).
In order to rule out any sex difference statistical analysis was
performed evaluating genotype 6 sex interaction for each
parameter by a two way-ANOVA. The following results were
obtained: swing (p = 0.001, F = 4.142), stride length variability
(p = 0.054, F = 2.221), paw angle variability (p = 0.114, F = 1.805),
paw area variability (p = 0.159, F = 1.612), vertical pole (p = 0.823,
F = 0.436), rotarod (p = 0.662, F = 0.651), resting time (p = 0.772,
F = 0.504), ambulatory time (p = 0.626, F = 0.700), vertical/
rearing time (p = 0.999, F = 0.045), jump time (p = 0.878,
F = 0.353), stereotypic time (p = 0.904, F = 0.311) and average
velocity (p = 0.450, F = 0.935). As no sex differences were found
among genotypes, males and females were used indistinctly.
Behavioral tests were performed during three consecutive days
as follows: first day, treadmill gait analysis and first training day of
rotarod; second day, vertical pole and second training day of
rotarod; and third day, four accelerating trials in the rotarod. The
first group of animals tested performed an additional open field
one day before starting behavioral tests.
Statistical analysis. Statistical analysis was performed with
SPSS 19.0. Data are presented as mean values 6 S.E.M. The
normality of the data was analyzed by Shapiro-Wilk test. Statistical
analysis of data with a normal distribution was performed
following a one way-ANOVA test followed by a DMS or a
Bonferroni post-hoc test. Statistical significance of non-parametric
data was determined by Kruskal-Wallis test when analyzing all
experimental groups, followed by a Mann-Whitney U-test for
analysis of paired genotypes and Bonferroni correction was
applied. Genotype frequencies were analyzed by means of chi-
square test. A critical value for significance of p,0.05 was used
throughout the study.
Results
Tet/DN-GSK-3 Mice in lpr Background are Viable and
Grow Normally
To explore whether the Fas dependent neuronal death observed
in lithium-treated mice [24] could be mimicked by inhibiting
GSK-3 via a dominant-negative genetic approach, we decided to
generate Tet/DN-GSK-3 mice in Fas-deficient background for
subsequent behavioral and brain apoptosis analysis. Mice
expressing DN-GSK-3 in forebrain neurons in a tetracycline
variability and paw angle variability was performed by applying one way-ANOVA test followed by a LSD post-hoc test. Statistical analysis of paw area
variability was performed using Kruskal-Wallis test for no parametric distribution of data. Then paired genotypes analysis was performed following a
Mann-Whitney U-test and Bonferroni correction was applied. *,# p,0.05; **,## p,0.01; ***,### p,0.001; * for wt vs. Tet/DN-GSK-3;# for Tet/DN-
GSK-3 vs. lpr/+;Tet/DN-GSK-3 and lpr/lpr;Tet/DN-GSK-3 mice. E-F. Analysis of motor coordination. E. Time to descend in vertical pole test. (wt, n = 16;
Tet/DN-GSK-3, n = 18; lpr/+, n = 28; lpr/+;Tet/DN-GSK-3, n = 23; lpr/lpr, n = 16 and lpr/lpr;Tet/DN-GSK-3, n = 10). Data are presented as the mean 6
s.e.m. time to descend the pole. Statistical analysis was performed applying a one way-ANOVA test followed by a LSD post-hoc test. *,# p,0.05. F.
Performance in the third and fourth accelerating trials represented as mean 6 s.e.m. time on rod (wt, n = 16; Tet/DN-GSK-3,n = 19; lpr/+, n = 28; lpr/
+;Tet/DN-GSK-3, n = 25; lpr/lpr, n = 16 and lpr/lpr;Tet/DN-GSK-3, n = 10). Statistical analysis was performed using Kruskal-Wallis analysis for no
parametric distribution of data. Then paired genotypes analysis was performed following a Mann-Whitney U-test.
doi:10.1371/journal.pone.0070952.g003
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repressible manner (Tet/DN-GSK-3 mice) were generated as
previously described [27] by combining mice expressing tTA
under CamKIIa promoter (tTA mice) with mice carrying myc-
K85R-GSK-3 and b-Gal sequences fused to a bidirectional tetO
promoter (tetO-R4 mice). Fas-deficient mice (lpr mice) are
naturally deficient in Fas receptor [35]. Double transgenic Tet/
DN-GSK-3 mice (that carry both the tTA-CamKIIa transgene,
and the TetO-R4 transgene) were then combined with lpr/lpr mice
as shown in Fig. 1A. Resulting lpr/+;Tet/DN-GSK-3 (F1) were
then bred with lpr/+ (F1) mice to obtain the six experimental
genotypes out of the twelve possible ones (Table 1). For
identification of genotypes, three different PCR reactions were
performed to detect the CamKII-tTA construct, the GSK-3
construct and the lpr mutation (Fig. 1B). To verify expression of the
transgene, western blot and immunohistochemistry of the b-gal
reporter were also performed (Fig. 1B). Analysis of the frequencies
by means of a chi-square test revealed that all genotypes adjusted
to the expected Mendelian distribution (Table 1) and they
displayed no overt phenotype. They also displayed body weight
similar to that of their control wild type (wt) littermates (Fig. 1C)
except for lpr/lpr mice that were bigger than wild type as
previously reported [36]. One-way ANOVA test (p = 0.026)
followed by Bonferroni post-hoc test was applied to determine the
level of significance and when males and females were tested
separately, a similar effect was found for lpr/lpr mice. However,
this difference was not evident in lpr/lpr mice harbouring any of
the Tet/DN-GSK-3 transgenes. For further biochemical, histo-
logical and behavioral analysis only wt, Tet/DN-GSK-3, lpr/+,
lpr/+;Tet/DN-GSK-3, lpr/lpr and lpr/lpr;Tet/DN-GSK-3 mice
were used and they were analyzed at the age of 2.5–3 months.
Absence of Apoptosis in Cortex and Striatum of Fas
Deficient-Tet/DN-GSK-3
For the analysis of apoptosis, immunofluorescence and immu-
nohistochemistry against cleaved (activated) caspase-3 and TU-
NEL staining were performed in the six experimental groups of
mice at the age of 2.5–3 months (Fig. 2). TUNEL is a common
method for detecting DNA fragmentation that results from
apoptotic signaling cascades and caspase 3 is one the major
caspases activated during the execution phase of apoptosis. First,
to verify that the cells undergoing apoptosis express the transgene,
we performed double immunofluoresce for caspase-3 and the
reporter b-gal (Fig. 2A). As described in our previous report [27],
double immunofluorescence with caspase-3 and NeuN (neuronal
marker) antibodies revealed an increase in the rate of apoptosis in
Tet/DN-GSK-3 mice respect to wild type mice with the majority
of apoptotic cells being neurons (Fig. 2B). For a more precise
quantification and comparison among the experimental groups
with varying lpr genotypes, immunohistochemistry of cleaved
caspase-3 was performed (Fig. 2C). Counting of positive caspase-3
cells confirmed the previously reported increased rate of apoptosis
in cortex (Cx) and striatum (St) of Tet/DN-GSK-3 mice respect to
their corresponding control wt littermates (wt vs. Tet/DN-GSK-3:
334.24633.61 vs. 578.816111.68 positive cells in Cx, p = 0.023;
546.52666.75 vs. 728.70621.47 positive cells in St, p = 0.01)
(Fig. 2C–D). As expected, no effect in the number of caspase-3
positive cells was detected in brain regions that do not express the
DN-GSK-3 transgene (TetO-R4 transgene) such as the thalamus
or the cerebellum. Interestingly, levels of cortical and striatal
apoptosis in Fas-deficient-Tet/DN-GSK-3 mice, either lpr/+;Tet/
DN-GSK-3 or lpr/lpr;Tet/DN-GSK-3, were similar to control
littermates (Tet/DN-GSK-3 vs. lpr/+;Tet/DN-GSK-3: p = 0.023
in Cx, p = 0.001 in St; Tet/DN-GSK-3 vs. lpr/lpr;Tet/DN-GSK-
3: p = 0.062 in Cx, p,0.000 in St). Therefore indicating that
apoptosis resulting after sustained inhibition of GSK-3 in striatum
and cortex is Fas dependent. Equivalent results were obtained
when apoptosis was analyzed by TUNEL method (wt vs. Tet/DN-
GSK-3: p = 0.007 in Cx, p = 0.01 in St; Tet/DN-GSK-3 vs. lpr/
+;Tet/DN-GSK-3: p = 0.004 in Cx, p = 0.005 in St; Tet/DN-
GSK-3 vs. lpr/lpr;Tet/DN-GSK-3: p = 0.007 in Cx, p = 0.005 in
St). (Fig. 2E–F, statistical analysis of cleaved caspase-3 immuno-
histochemistry and TUNEL was performed following a one way-
ANOVA test followed by a LSD post-hoc test). Furthermore, since
the absence of DN-GSK-3 mediated apoptosis is not only seen in
homozygous lpr/lpr background but also in the heterozygous lpr/+
background, just a partial attenuation of Fas-dependent signaling
is sufficient to preclude the effect of DN-GSK-3 on apoptosis
induction.
Absence of Motor Deficits in Tet/DN-GSK-3 Mice in lpr
Background
Increased apoptosis in Tet/DN-GSK-3 is more prominent in
striatum and cortex which are part of the basal ganglia circuit,
involved in motor control. Accordingly, Tet/DN-GSK-3 mice
have been reported to show deficits in motor tasks like the vertical
pole and the footprint tests [27]. Since we have found no evidence
of increased neuronal death in striatum and cortex of Tet/DN-
GSK-3 mice with Fas deficiency (lpr/+ or lpr/lpr;Tet/DN-GSK-3),
we wondered whether motor deficits observed in Tet/DN-GSK-3
mice would also be absent in Fas-deficient Tet/DN-GSK-3 mice.
To that end, the six experimental groups of mice were subjected to
several behavioral tests that detect potential deficiencies in motor
tasks. First we performed DigiGait test, which measures footprint
pattern and other parameters of walking regularity (Fig. 3A–D). In
good agreement with our previous report [27], Tet/DN-GSK-3
mice subjected to analysis of DigiGait parameters showed multiple
gait abnormalities such as increased swing duration (ANOVA,
p = 0.006, F = 3.374; Fig. 3A), increased variability in stride length
(ANOVA, p = 0.043, F = 2.342; Fig. 3B), increased paw angle
variability (ANOVA, p = 0.000, F = 10.306; Fig. 3C) and increased
paw area variability (Kruskal-Wallis, p = 0.000; Fig. 3D) as
compared to wt mice. Interestingly, lpr/+;Tet/DN-GSK-3 and
lpr/lpr;Tet/DN-GSK-3 showed no abnormalities compared with
their respective controls. Statistical analysis of swing duration,
stride length variability and paw angle variability was performed
by applying one way-ANOVA test followed by a LSD post-hoc test
while analysis of paw area variability was performed using
Kruskal-Wallis test for no parametric distribution of data. Then
paired genotypes analysis was performed following a Mann-
Whitney U-test and Bonferroni correction was applied. In
summary, these results indicate that the increased variability in
walking regularity found in Tet/DN-GSK-3 mice is reduced in
Fas-deficient backgrounds.
We then performed tests of striatal-dependent motor coordina-
tion like the vertical pole and the rotarod tests (Fig. 3E–F). In good
agreement with the above shown results, we found significantly
increased time to descend the vertical pole for Tet/DN-GSK-3
mice with respect to their control wt littermates (wt vs. Tet/DN-
GSK-3: 1762.2s vs. 1060.8s, ANOVA: p = 0.036, F = 2.485).
Interestingly, the difference was smaller and not significant
between lpr/+;Tet/DN-GSK-3 (1261.1s) or lpr/lpr;Tet/DN-
GSK-3 (1261.6s) and their respective controls (Fig. 3E). Statistical
analysis was performed applying a one way-ANOVA test followed
by a LSD post-hoc test. The accelerating rotarod is another test that
detects striatal dependent deficits in motor coordination. This test
measures the time spent by the mouse on a rotating cylinder (rod)
as the speed of rotation is accelerating from 4 to 40 r.p.m. Results
of rotarod test were represented as average of third and fourth
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trials (Fig. 3F). Despite a tendency to decreased time on rod of
Tet/DN-GSK3 mice (wt vs. Tet/DN-GSK-3: 22568.26 vs.
199615.1, p = 0.101 in Kruskal-Wallis analysis followed by
Mann-Whitney U-test.), no significant difference was observed
for any group. Finally, to verify that these animals do not show
impairment in general locomotive behavior, they were subjected to
open field test (Fig. S1) and several parameters as inactivity time
(p = 0.289, F = 1.277; Fig. S1A), horizontal activity (p = 0.116,
F = 1.876; Fig. S1B), vertical activity (p = 0.0.064, F = 2.511; Fig.
S1C), jump time (p = 0.788; Fig. S1D), stereotypic movements
(p = 0.0.271, F = 1.32; Fig. S1E) or average velocity (p = 0.098,
F = 1.982; Fig. S1F), were measured and no differences among
genotypes were found. Statistical analysis was performed applying
a one way-ANOVA test except for jump time for that a Kruskal-
Wallis test was applied.
Discussion
By combining conditional transgenic mice with neuronal
expression of a dominant negative form of GSK-3 (Tet/DN-
GSK-3 mice) and lpr mice, we have generated mice with sustained
inhibition of GSK-3 in a Fas-deficient background for analysis of
apoptosis in brain and for behavioral characterization of their
ability to carry out motor tasks. Unlike Tet/DN-GSK-3 mice that
show increased apoptosis in cortex and striatum [27], lpr/+;Tet/
DN-GSK-3 and lpr/lpr; Tet/DN-GSK-3 mice showed levels of
neuronal apoptosis similar to those found in wild type mice. In
addition, analysis of motor coordination in tests of walking
regularity, in the vertical pole test and in the rotarod test revealed
that the motor deficits previously reported in Tet/DN-GSK-3
mice [27] were no longer evident when genetic inhibition of GSK-
3 occurs in a Fas-deficient background.
Lithium prescription to bipolar disorder patients has decreased
in the last years due to its common side effects [37,38].
Understanding the molecular mechanism by which lithium exerts
its neurological toxicity may lead to strategies to overcome its side-
effects. In this regard, inhibition of GSK-3 by lithium has been
postulated to contribute not only to its therapeutic efficacy [8,9,10]
but also to its neurological toxicity [24]. Since increased GSK-3
activity is believed to contribute to the etiology of other
pathologies such as AD, lithium has been postulated as a possible
therapy for AD [19]. However, despite potential benefits of lithium
for amnestic minimal cognitive impairment in a recent trial [39],
clinical trials for AD have been hampered by high rates of
discontinuation due to lithium’s adverse effects that is even more
prominent in the elderly [40]. Therefore, toxicity of lithium
therapy is a problem that extends beyond mood disorders.
Regarding the molecular basis of lithium toxicity, we have recently
reported a mechanism for the neurological toxicity of chronic
lithium in mice that is dependent on Fas signaling [24]. As
mentioned, lithium also inhibits other enzymatic activities such as
inositol monophosphatase and histone deacetylase [31]. Although
this study does not provide direct evidence that decreasing Fas
would decrease toxicity associated with lithium treatment, the
results reported here demonstrate that neuronal apoptosis and
motor deficits caused by sustained GSK-3 inhibition are Fas
dependent. It is therefore conceivable that Fas signaling modulat-
ing drugs could be used in the future to improve clinical use of
lithium not only for bipolar disorder but also for AD. Besides,
more selective GSK-3 inhibitors are currently under development
[19,41], and, similar to lithium, they are known to attenuate
neuronal loss in AD animal models with increased GSK3 activity
(such b-Amyloid infusion) but also to induce neuronal apoptosis
when administered alone to wild type animals without any GSK-3
increasing stimulus [42]. Therefore, modulation of Fas signaling
might contribute to the successful application of selective GSK-3
inhibitors to clinics in general.
It is worth noting that factors that attenuate Fas signaling have
been suggested per se as a potential avenue for therapeutic
intervention for AD [43] since increased levels of Fas protein have
been reported in the brain and cerebrospinal fluid of AD patients
[44,45] and the Fas gene is located in the 10q24.1 region showing
linkage to late onset AD [46,47] with polymorphisms in Fas having
shown association with AD progression [48,49]. What would
increase the chances of success of a combination of GSK-3
inhibitors and Fas signaling-blockers for AD.
Apart from the mentioned Fas-dependent mechanism for
lithium- or genetic GSK-3 inhibition-induced apoptosis there is
another reported mechanism by which decreased GSK-3 activity
could contribute to exacerbate apoptosis through the extrinsic
pathway [50]. More precisely, GSK-3 has been reported to act at
an intracellular juxtamembrane location in association with
DDX3, the cellular inhibitor of apoptosis protein-1 (cIAP-1) and
any of the death receptors to form an antiapoptotic complex.
When GSK-3 activity is blocked, stimulation of death receptor
potentiates caspase-3 activation [50]. Therefore and in regard to
the other above mentioned mechanisms requiring Fas activation,
both mechanisms converge in the activation of a death receptor.
As in our present study we have blocked apoptosis at the level of
Fas (by using Fas-deficient mice), we cannot conclude if
stimulation of the receptor or disassembly of the antiapoptotic
complex, is predominant. Further experiments specifically aiming
blockade of Fas signaling upstream or at the inhibitory complex
would be needed to elucidate the contribution of both proposed
mechanisms to apoptosis.
One interesting feature of the results reported here is that
heterozygous lpr modification of Fas is sufficient to correct both the
apoptotic and the motor phenotypes of Tet/DN-GSK-3 mice.
Therefore, provided the case that pharmacological inhibitors of
Fas are developed in the future to facilitate lithium- of more
selective GSK-3 inhibitor-based therapies, it is possible that just a
partial attenuation of Fas-dependent signaling might sufficient to
preclude the effect of GSK-3 inhibitors on apoptosis induction.
However, we should also keep in mind the potential drawbacks of
prospective Fas inhibiting therapies as Fas signaling is required for
many aspects of brain physiology such as neural progenitor
survival [51].
An open question remains regarding the results reported here as
whether the apoptosis observed in Tet/DN-GSK-3 mice and that
disappears in the absence of fully functional Fas receptors is
required for the motor phenotype that also gets normalized in a
Fas deficient background. In fact, despite higher than in wild type
mice, apoptotic rate in Tet/DN-GSK-3 mice is still low and does
not produce a visible atrophy of affected structures. Alternatively,
the effect in motor coordination could be caused not by the loss of
a limited number of neurons in the circuit but by an alteration in
the physiology of the global brain structure or circuit. In fact, our
group has previously demonstrated that in a mouse model of
striatal degeneration (HD94 mice) alterations in motor coordina-
tion occur in the absence of striatal cell loss, presumably by
dysfunction of striatal neurons [52]. It is therefore possible that Fas
signaling may also affect physiology of healthy neuronal circuits
[53,54,55]. Thus an excessive Fas-FasL signaling could result in
apoptosis of a limited number of neurons and in a more
widespread dysregulation of neuronal physiology thus contributing
to the behavioral consequences induced by GSK-3 inhibition.
In summary, here have genetically proven that neuronal
apoptosis and motor deficits caused by sustained GSK-3 inhibition
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are Fas dependent. This might have important implications to
enable combined therapies that could facilitate the clinical use of
lithium and or more selective GSK-3 inhibitors not only for
bipolar disorder but also for other diseases in which excess GSK-3
activity is believed to contribute to pathogenesis.
Supporting Information
Figure S1 All genotypes show similar general locomo-
tive behavior. Analysis of several parameters in open field test.
Analysis of inactivity time (A), horizontal activity (B), vertical
activity (C), jump time (D), stereotypic movements (E) or average
velocity (F) was performed and no differences among genotypes
were found. Statistical analysis was performed applying a one way-
ANOVA test except for jump time for that a Kruskal-Wallis test
was applied.
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